Welcome to our dedicated page for Intuitive Surgical SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical (ISRG) CEO and Director David J. Rosa reported an insider gift of 5,454 shares of common stock on 11/03/2025, coded G for gift at $0.0 per share. Following the transaction, he directly holds 228,802 shares. The filing notes the shares were gifted to The Rosa Donor Advised Fund.
Intuitive Surgical (ISRG) insider activity: EVP & Chief Medical Officer Myriam Curet reported option exercises and open‑market sales under a Rule 10b5‑1 trading plan. On 10/28/2025, she exercised 5,030 options at $242.3367, 1,153 at $229.39, and 1,379 at $208.9, then sold the corresponding shares at a weighted average price of $548.4254. On 10/29/2025, she exercised 125 options at $208.9 and sold those shares at $543.
After these transactions, direct holdings were 0 shares; indirect holdings were 353 shares held by a trust. Footnotes note the plan expires July 29, 2026 and provide vesting schedules under the company’s 2010 Incentive Award Plan.
Intuitive Surgical (ISRG) insider Gary S. Guthart, Executive Chair and Director, reported insider transactions on 10/24/2025. He exercised 36,000 non-qualified stock options at an exercise price of $109.4856 and sold shares the same day under a prearranged plan.
Dispositions included 28,800 shares at a weighted average price of $547.5571, plus additional sales of 1,400 shares at $546.3499 and 1,400 shares at $546.184. The filing states the trades were made under a Rule 10b5-1 trading plan that expires on April 28, 2026, with sale price ranges and undertakings to provide full breakdowns upon request.
Intuitive Surgical (ISRG): Director transaction disclosed. Director Craig H. Barratt exercised a non-qualified stock option for 2,193 shares at an exercise price of $71.3233 on 10/24/2025 and sold 2,193 shares at $548.01 the same day under a Rule 10b5-1 trading plan.
Following the transactions, direct common stock holdings were 0 shares, and indirect holdings were 27,198 shares held by a trust. The filing also reports 750 derivative securities (options) remaining beneficially owned directly. The trading plan complies with Rule 10b5-1 and expires on April 29, 2026. The option was granted under the Non-Employee Directors' Stock Option Plan with vesting as noted in the plan terms.
Intuitive Surgical (ISRG) CEO David J. Rosa reported insider transactions on 10/24/2025. He exercised 27,000 non-qualified stock options at an exercise price of $79.6378 per share and sold 24,500 shares of common stock at a weighted average price of $547.5502.
The sales were executed under a Rule 10b5-1 trading plan that expires on June 11, 2026, with individual trade prices ranging from $542.16 to $550.21. Following these transactions, Rosa beneficially owns 234,256 shares directly. The exercised option, granted under the 2010 Incentive Award Plan, carries an expiration date of 02/15/2027 and vested per a stated schedule.
Intuitive Surgical (ISRG) reported strong Q3 2025 results. Revenue rose to $2,505.1M from $2,038.1M a year ago, led by instruments and accessories $1,518.8M, systems $590.4M, and service $395.9M. Net income was $704.4M with diluted EPS of $1.95 (vs. $1.56), and income from operations reached $759.7M. U.S. revenue was $1,717.6M; outside the U.S. was $787.5M.
Cash and cash equivalents were $2,806.6M and short‑term investments $2,102.2M as of September 30, 2025. Year‑to‑date cash from operations was $2,138.0M. The company repurchased $1,919.6M of stock in Q3 at an average price of $479.60; authorization remaining was about $1.9B. Remaining performance obligations were $2.88B. Intuitive outlined a pending acquisition of da Vinci and Ion distribution businesses in Italy, Spain, Portugal, Malta, and San Marino for EUR 290M upfront plus up to EUR 31M in milestones, subject to approvals and expected in the first half of 2026.
Legal updates included an appeals court affirming a prior judgment in the Rex Medical matter and a trial court ruling in Intuitive’s favor on SIS antitrust claims; a related class action was certified, with no trial date set.
Intuitive Surgical (ISRG) furnished an 8-K announcing quarterly results. On October 21, 2025, the company issued a press release with financial results for the quarter ended September 30, 2025, attached as Exhibit 99.1. The materials are furnished and not deemed filed under the Exchange Act.
Gary Loeb, EVP & Chief Legal and Compliance at Intuitive Surgical (ISRG), reported beneficial ownership changes on 10/10/2025. A vesting event converted 2,612 restricted stock units into common shares (transaction code M), with net shares deposited after withholding for taxes. Immediately following the vesting, the filing shows a sale/disposition of 1,296 shares at $443.76 (transaction code F), leaving the reporting person with 3,561 shares beneficially owned. The RSU grant vests 25% annually over four years, and the filing notes that 25% of the grant was released at this vesting date.
Amy L. Ladd, a director of Intuitive Surgical, reported two scheduled sales of common stock under a Rule 10b5-1 trading plan that expires on June 4, 2026. She sold 336 shares on 09/03/2025 at an average price of $470.11 and 335 shares on 09/04/2025 at an average price of $440.69. After the transactions she beneficially owned 1,074 shares following the first sale and 739 shares following the second sale. The filing is a Form 4 disclosure of changes in beneficial ownership and indicates the trades were made pursuant to a pre-established trading plan.
Intuitive Surgical Inc. (ISRG) Form 144 shows a proposed sale of 335 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $147,631.15, targeted for 09/04/2025. The shares were acquired as restricted stock on 04/25/2024 from the issuer. The filer represents no undisclosed material information. The filing also reports a separate sale by Amy L. Ladd of 336 shares on 09/03/2025 for $157,956.96. The issuer's reported shares outstanding are 358,476,506, indicating these transactions represent a very small fraction of total equity.